MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.hbpd.2026.01.009

Медицинская библиотека · Hepatobiliary & pancreatic diseases international : HBPD INT · 2026

Safety and efficacy of liver transplantation for hepatocellular carcinoma with bile duct tumor thrombus: A single-arm, multicenter, prospective study.

Lan Tian-Chen, Chen Jian, Yang Zhe, Wu Sheng-Dong, Lu Qian, Lou Cheng-Tao, Hu Xin-Hao, Chen Yi-Jian, Wang Kai, Liu Peng, Liu Yan-Peng, Gao Ming-Wei, Li Jian-Hua, Xu Gang, Sun Xu-Yong, Dou Jian, Guo Wen-Zhi, Lv Guo-Yue, Liu Chao, He Qiang, Zhu Ji-Ye, Yang Yang, Liu Lian-Xin, Zhu Zhi-Jun, Li Guang-Ming, Zhou Jian, Chen Zhi-Shu, Lv Yi, Fu Zhi-Ren, Qi Hai-Zhi, Ye Qi-Fa, Wang Zheng-Xin, Wang Li-Ming, Cai Jin-Zhen, Li Xiang-Cheng, Xia Qiang, Dong Jia-Hong, Lu Cai-De, Zheng Shu-Sen, Yang Jia-Yin, Xu Xiao

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

The prognosis for patients diagnosed with hepatocellular carcinoma with bile duct tumor thrombus (HCC-BDTT) remains dismal, and there are presently no universally accepted treatment guidelines to address this complex condition. Long-term outcomes of liver transplantation (LT) for HCC-BDTT patients are unclear, and whether LT is a proper therapeutic option for HCC-BDTT patients remains to be determined. Therefore, we design a clinical trial to evaluate whether LT can improve recurrence-free survival (RFS) and overall survival (OS) in HCC-BDTT patients. This is an open-labeled, single-arm, prospective, multicenter and real-world study aiming to assess the survival outcomes of HCC-BDTT patients in LT. Patients will be enrolled based on histological confirmation of HCC with BDTT. The study is planned to take 4 years, 2 years for enrollment and 2 years for follow-up. We anticipate that LT confers beneficial survival outcomes for HCC-BDTT patients, specifically in terms of the pivotal parameters, such as RFS and quality of life. Upon successful completion of the trial, we will extend our monitoring over a longer follow-up time to accurately estimate important indicators such as OS. We expect that this study provides substantial evidence to refine treatment guidelines through thorough data analysis, ultimately contributing to better patient outcomes and advancing our understanding of the disease. TRIAL REGISTER: Trial registered at www.clinicaltrials.gov (NCT06928415).

Для цитирования: Lan Tian-Chen, Chen Jian, Yang Zhe, Wu Sheng-Dong, Lu Qian, Lou Cheng-Tao, Hu Xin-Hao, Chen Yi-Jian, Wang Kai, Liu Peng, Liu Yan-Peng, Gao Ming-Wei, Li Jian-Hua, Xu Gang, Sun Xu-Yong, Dou Jian, Guo Wen-Zhi, Lv Guo-Yue, Liu Chao, He Qiang, Zhu Ji-Ye, Yang Yang, Liu Lian-Xin, Zhu Zhi-Jun, Li Guang-Ming, Zhou Jian, Chen Zhi-Shu, Lv Yi, Fu Zhi-Ren, Qi Hai-Zhi, Ye Qi-Fa, Wang Zheng-Xin, Wang Li-Ming, Cai Jin-Zhen, Li Xiang-Cheng, Xia Qiang, Dong Jia-Hong, Lu Cai-De, Zheng Shu-Sen, Yang Jia-Yin, Xu Xiao. Safety and efficacy of liver transplantation for hepatocellular carcinoma with bile duct tumor thrombus: A single-arm, multicenter, prospective study.. Hepatobiliary & pancreatic diseases international : HBPD INT. 2026. DOI: 10.1016/j.hbpd.2026.01.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.